Xenon Pharmaceuticals (NASDAQ:XENE) Reaches New 1-Year High Following Analyst Upgrade

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) reached a new 52-week high on Monday after Wells Fargo & Company raised their price target on the stock from $49.00 to $68.00. Wells Fargo & Company currently has an overweight rating on the stock. Xenon Pharmaceuticals traded as high as $62.64 and last traded at $59.71, with a volume of 5611537 shares traded. The stock had previously closed at $41.94.

A number of other research analysts also recently commented on the company. Jefferies Financial Group set a $100.00 target price on Xenon Pharmaceuticals in a research note on Monday. Deutsche Bank Aktiengesellschaft raised their price target on Xenon Pharmaceuticals from $56.00 to $90.00 and gave the stock a “buy” rating in a research note on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a report on Friday, January 9th. Stifel Nicolaus set a $66.00 price target on Xenon Pharmaceuticals in a research note on Tuesday, February 10th. Finally, Morgan Stanley set a $97.00 price objective on Xenon Pharmaceuticals in a report on Monday. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $71.94.

Insider Activity

In other news, CEO Ian Mortimer sold 40,000 shares of the stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $44.43, for a total transaction of $1,777,200.00. Following the transaction, the chief executive officer owned 6,000 shares of the company’s stock, valued at approximately $266,580. This represents a 86.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 4.07% of the company’s stock.

Key Stories Impacting Xenon Pharmaceuticals

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Phase 3 X‑TOLE2 topline results show azetukalner produced a statistically significant reduction in focal‑onset seizure frequency, positioning the drug for an NDA submission targeted in Q3 2026 — a major clinical milestone that drove the earlier sharp rally. GlobeNewswire: X-TOLE2 Results Reuters: Trial Meets Main Goal
• Positive Sentiment: Multiple brokerages raised price targets and maintained bullish ratings (HC Wainwright, Deutsche Bank, Needham, Wells Fargo, Wedbush), reflecting upwardly revised sales and valuation assumptions after the Phase 3 readout. Benzinga: Analyst Upgrades
• Neutral Sentiment: Trading was temporarily halted ahead of the announcement, indicating the exchange processed material news that subsequently drove heavy intraday activity. (News pending/halt was lifted following the topline release.)
• Neutral Sentiment: Yesterday’s massive intraday rally — driven by the trial news — created rapid re‑rating and higher volatility; that squeeze can produce follow‑through profit‑taking and larger volume swings. 247WallSt: Big One‑Day Gain
• Negative Sentiment: Xenon announced a proposed underwritten public offering of $500M of common shares (with a 30‑day option for an additional $75M). Issuing new equity after a large run‑up creates dilution risk and puts selling pressure on the stock even though proceeds could fund commercialization and ongoing trials. GlobeNewswire: Offering MSN: Offering Coverage

Institutional Investors Weigh In On Xenon Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in XENE. Kestra Advisory Services LLC acquired a new position in Xenon Pharmaceuticals during the fourth quarter valued at approximately $33,000. Blue Trust Inc. raised its position in shares of Xenon Pharmaceuticals by 2,560.7% in the fourth quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 717 shares during the period. Danske Bank A S acquired a new stake in shares of Xenon Pharmaceuticals in the third quarter worth $32,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Xenon Pharmaceuticals in the fourth quarter worth $43,000. Finally, Aster Capital Management DIFC Ltd bought a new stake in shares of Xenon Pharmaceuticals during the 3rd quarter worth $39,000. Institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Trading Down 3.4%

The company’s fifty day moving average is $42.95 and its 200-day moving average is $41.56. The firm has a market capitalization of $5.04 billion, a P/E ratio of -13.90 and a beta of 0.91.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.11). During the same period in the previous year, the company posted ($0.84) EPS. On average, equities research analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current year.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.